This study describes MDR-TB treatment models in three countries-Peru, Russia and Lesothousing qualitative data collected over a 13-year period.
B A C K G R O U N D : Although multidrug-resistant tuberculosis (MDR-TB) is a major global health problem, there is a gap in programmatic treatment implementation. M E T H O D S :
This study describes MDR-TB treatment models in three countries-Peru, Russia and Lesothousing qualitative data collected over a 13-year period.
R E S U LT S :
A program analysis is presented for each country focusing on baseline medical care, initial implementation and program evolution. A pattern analysis revealed six overarching themes common to all three programs: 1) importance of baseline assessments, 2) early identifi cation of key collaborators, 3) identifi cation of initial locus of care, 4) minimization of patient-incurred costs, 5) targeted interventions for vulnerable populations and 6) importance of technical assistance and funding. Site commonalities and differences in each of these areas were analyzed.
C O N C L U S I O N S : It is recommended that all programs providing MDR-TB treatment address these six areas during program development and implementation. K E Y W O R D S :
TB; MDR-TB; Peru; Russia; Lesotho MULTIDRUG-RESISTANT tuberculosis (MDR-TB) is a growing problem globally, with an estimated 440 000 new cases annually. 1 Although treatment options have been available since the 1980s, 2 less than half of 1% of cases have been enrolled in treatment with quality assured drugs. 3 Multiple reasons have been cited to explain the failure of MDR-TB treatment scale-up. [4] [5] [6] Some experts have cited a lack of successful treatment models for implementing MDR-TB treatment programs. We seek to address this gap in the literature by describing treatment models for expanding access to MDR-TB treatment in Peru, Lesotho and the Russian province of Tomsk.
METHODS
This study was conducted using qualitative methods in a variety of health settings, 7 including participant observation, ethnographic interviewing, key informant interviewing and focus group discussions. Data and fi eld notes were kept and analyzed for content and pattern. These ethnographic techniques were employed over a 13-year period and supervised by a trained anthropologist (JF). Data were analyzed and compared across settings by two members of the team (JF, PF). A program analysis was performed for each site, focusing on baseline health care, initial program implementation and program evolution. Additional analysis of the data revealed six overarching themes: 1) importance of baseline assessments, 2) early identifi cation of key collaborators, 3) identifi cation of initial locus of care, 4) minimization of patient-incurred costs, 5) targeted interventions for vulnerable populations, and 6) importance of technical assistance and funding. These were compared in each setting and are presented in the theme analysis section below.
RESULTS

Settings
The programs described in this article were implemented in Lima, Peru; Tomsk, Russia; and Lesotho by the non-governmental organization (NGO) Partners In Health (PIH), its local sister organizations, and the corresponding national tuberculosis programs (NTPs). Table 1 lists some key health and socio-economic indicators at the time the programs started. 8, 9 Program analysis Lima, Peru Baseline health system. In 1996, health care in Lima was provided using a primary care model, with health centers serving as the initial point of contact
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1295 with referral to district hospitals for complicated care. Community health workers (CHWs), known as promotores, were recognized by the Ministry of Health, but were neither organized nor paid. TB care was provided at the health centre level using DOTS. Smear microscopy was available at health centers, cultures were performed at district laboratories and fi rst-line drug susceptibility testing (DST) could be performed at the central National Reference Laboratory. First-line anti-tuberculosis drugs were available free of charge and second-line medications were available on the free market. Although political will for DOTS was high, there was little recognition of MDR-TB or interest in treating such cases. 10 Initial implementation. In 1995, 12 cases of MDR-TB were identifi ed in a slum in northern Lima after an American priest working there died of the disease. In 1996, PIH and its partners began to treat 10 of these patients using ambulatory (i.e., in health centers) and community-based care (i.e., directly observed treatment [DOT] in patients' homes by trained and paid CHWs). Individualized regimens were tailored to drug resistance data and treatment history. 11 The treatment team consisted of Ministry of Health (MOH) providers, US-based technical advisors (two of whom lived in Lima during the initial implementation), and a community-based team employed by the NGO's sister organization, Socios En Salud (SES). The Massachusetts State Laboratory Institute (MSLI) provided laboratory services. Drugs were procured privately through a US hospital. Initial political support in Peru was limited, but local MOH providers were directly involved in patient care. All patients received free medication and nutritional and transportation support. The program scaled up to 75 patients in three districts of Lima over the next 18 months, achieving treatment outcomes comparable to those in the United States. 12 Program evolution. The fi rst stage of scale-up was from three districts to all of metropolitan Lima. 13 By 2004, the program had enrolled more than 800 patients, demonstrating programmatic feasibility. Policy shifts at the World Health Organization (WHO) 14 ultimately led to increased political will in Peru, and in 2000, the MOH assumed leadership of the program with technical assistance from SES. Scale-up involved training of regional teams, as well as recruitment of additional community-based nurses and CHWs. More than 15 000 patients have received MDR-TB treatment in Peru since 1996. 15 Both standardized and individualized regimens are delivered in health centers and patient homes, the latter delivered by paid CHWs. Patients are given food and transportation support during the initial months of treatment. The MSLI provided technical assistance to the National Reference Laboratory in Peru to validate and implement fi rst-and second-line DST, as well as handle the increased demand for cultures. Reliable drug procurement was established through the Green Light Committee (GLC) and managed through a central pharmacy in Lima. Funding for initiation was provided by private donations, and costs for the initial program (1996-1998) were approximately US$1.7 million. Later funding was provided by the Bill & Melinda Gates Foundation and has now transitioned to the Global Fund for AIDS, TB and Malaria (Global Fund) and the Peruvian NTP.
Tomsk, Russia
Baseline health system. In 1999, health care in Tomsk was provided using a clinic and hospital-based system. Care was provided by physicians and nurses, with feldshers (i.e., health technicians) providing services in remote regions. TB care was provided at TB dispensaries throughout the oblast, where the DOTS strategy had been adopted in 1994, with assistance from an NGO (Merlin). Patient care was provided in a TB hospital, day hospital or polyclinic. Medically or socially complex patients were usually treated as inpatients. The day hospital provided treatment to patients from early morning until evening, including meals for patients. Social support and incentives were an inherent component of Russian TB services. 16 The prison health care system functioned largely apart from the civilian health sector. 17 For both systems, smear microscopy, culture and fi rst-line DST were widely available throughout the oblast, and both cultures and fi rst-line DST could be performed at central facilities. First-line TB drugs were available free of charge, while second-line medications were available on the free market. At the national level, political will was strongest within the prison system (Ministry of Justice [MOJ]), while collaboration was strong at the oblast level in both civilian and prison sectors.
Initial implementation. In the late 1990s, high rates of MDR-TB were described in the former Soviet Union, 18, 19 particularly among prisoners. 20, 21 Tomsk houses a large TB prison, and an alarming number of MDR-TB cases were noted. 22 The Russian MOJ requested assistance from PIH, and in 1998, the Open Society Institute (OSI), PIH, Tomsk Oblast Tuberculosis Services (TOTBS), the MOJ, and the Public Health Research Institute (PHRI) initiated a program in Tomsk Oblast to treat prisoners with MDR-TB. Starting with 38 patients, individualized regimens tailored to drug resistance data and treatment history were administered under strict DOT. 23 The treatment team consisted of MOJ providers at the prison and four US-based physician advisors. In addition to receiving medications free of charge, all patients received additional protein rations throughout treatment. MDR-TB patients were housed separately from those with pan-susceptible disease. The MSLI assisted the Russian laboratory system in instituting external quality assurance for DST. Drugs were procured in the United States, registered in Russia and donated to the TOTBS. Political will remained strong in the oblast.
Program evolution. Four months after initiation of the prison-based program, treatment was quickly expanded to the civilian sector. The civilian team of TOTBS physicians collaborated closely with MOJ physicians and US collaborators. Civilian patients were initially treated as in-patients. However, as the TB hospital fi lled, stable patients were transitioned to ambulatory treatment sites, with provision of nutritional and socio-economic support by the Red Cross. In more remote regions, treatment was given at TB dispensaries or at home by feldshers. In the fi rst year of the program, 244 patients were enrolled for MDR-TB treatment. 24 By 2004, the project had achieved coverage throughout Tomsk Oblast. To date, more than 1700 patients have received MDR-TB treatment, and MDR-TB and TB incidence have declined in the oblast. Care is provided by Russian providers in prisons, hospitals, ambulatory sites and at home. The Tomsk laboratory system is used for DST. Drugs are obtained through the GLC and managed at a central pharmacy in Tomsk. Intensive social support for patients is provided through a program called 'Sputnik', which identifi es patients at greatest risk for default and provides them with home-based DOT and nutritional and transportation support. The Tomsk TB Alcohol Working Group was also established to employ evidencebased strategies to reduce the impact of alcohol consumption on TB control. 25 Political support has deepened locally and at the national level; TOTBS and PIH have worked with the Russian Medical Academies to develop national norms for management of MDR-TB (Prikaz 109). Funding for the fi rst 12 months of the program (US$2.2 million) was provided by the OSI. Ongoing funds have come from the Bill & Melinda Gates Foundation, the World Bank, the Eli Lilly Foundation and the Global Fund.
Lesotho
Baseline health system. In 2006, primary health care in Lesotho was provided by nurses and nursing assistants at health centers. Due to extreme health care worker shortages 26 and a national human immunodefi ciency virus (HIV) seroprevalence of 24%, 27 most health centers were non-functional. Despite the NTP policy of universal TB treatment at health centers, very few patients were diagnosed or treated for TB. TB care was largely provided at district hospitals using facility-based DOTS, and complicated patients were referred to the national hospital in Maseru. CHWs worked with health centers, but most were not providing care and none were paid. Smear microscopy was only available at the central laboratory and cultures and DST were not available in the country. 28 First-line drugs were provided free of charge, and both aminoglycosides and fl uoroquinolones were available on the open market. Political will was strong, but the MOH lacked the staff and funding to manage TB adequately. Further complicating TB care were the high rates of HIV co-infection in TB patients, estimated to be 70-90%. 29 Initial implementation. PIH began working in Lesotho in February 2006, assisting in HIV prevention and treatment scale-up. 30 In 2007, following an outbreak of extensively drug-resistant TB (XDR-TB) in neighboring KwaZulu-Natal, 31 a small survey conducted with the support of the MSLI documented several cases of MDR-TB in Lesotho. In 2007, a centralized MDR-TB treatment program was established by PIH and the NTP. 32 Ten patients were enrolled in a hospital-based treatment program after a local health facility was equipped with proper infection control. Patients were treated with individualized regimens and rapidly initiated on antiretroviral treatment (ART) if they were HIV-positive. The program was staffed by a local physician, two US physicians, and a team of MOH nurses and paid CHWs from both the HIV and the TB programs. Patients were given nutritional support. Culture and DST were performed in South Africa, while the Foundation for Innovative and New Diagnostics (FIND) started improving the laboratory at the central hospital in Maseru. Drugs were procured from the GLC and stored in a central pharmacy in Maseru. Political will remained high, with the MOH actively engaged on all levels. In the fi rst year of implementation, 76 patients were enrolled for treatment.
Program evolution. The program was formally assumed by the MOH in 2009. By 2010, the program was decentralized into all 10 health districts in Lesotho; the project has enrolled 300 patients to date. Individualized regimens and rapid initiation of ART remain the common treating principles. Default is less than 5%, but given the late diagnoses and concomitant HIV, treatment success is about 60%. 33 Patients are initially stabilized in the TB hospital and rapidly discharged home for ongoing care from paid CHWs. For patients from remote areas, temporary housing is provided in Maseru. 34 Patients receive nutritional, housing and transportation support. Care is still provided by PIH and MOH physicians and nurses from both the TB and the HIV programs, including seven local physicians. Additional MOH CHWs have been recruited, and it is now the norm for all CHWs in Lesotho to be paid. The improved laboratory was completed and functioning within 8 months, and now provides on-site culture, Mycobacterial Growth Indicator Tube-based DST and rapid rifampin testing. Drugs are procured through the GLC and stored in the central Maseru pharmacy. Political will remains strong. Initial funding for the project was provided by the OSI for a total of US$3 million for the fi rst 3 years, including the costs of building the laboratory and the in-patient facility. Ongoing funding comes through the Global Fund.
Theme analysis
The following six overarching themes emerged in all three settings and are compared across the sites in this section: 1) importance of baseline assessments, 2) early identifi cation of key collaborators, 3) identifi cation of initial locus of care, 4) minimization of patient-incurred costs, 5) targeted interventions for vulnerable populations and 6) importance of technical assistance and funding.
Importance of baseline qualitative assessments
All sites carried out baseline and ongoing qualitative assessments to determine needs and adaptations required for program improvements. In each site, the baseline and ongoing assessments were performed by medical anthropologists with expertise in MDR-TB management. Initial assessments included a rapid health systems survey performed in parallel with participant observation, key informant interviewing and focus group discussions. Once the baseline assessments were complete, ongoing participant observation, interviews and focus groups were done in patient, policy and program settings. Explanatory models of care and cultural factors related to care were also explored.
Early identifi cation of key collaborators and personnel
All three sites identifi ed the MOH and public sector programs under the NTP as necessary collaborators. The nature of these MOH collaborations varied by site. Early collaboration was complicated in Peru, largely because MDR-TB treatment was not accepted internationally. Once the program had gained international recognition, national MOH leadership assumed responsibility for programmatic scale-up. In Tomsk, strong collaborators were involved at the oblast level, but national sanction by the Russian MOH and MOJ was also required. Once the project had demonstrated success, PIH actively fostered collaboration around training and policy development with leaders in the Russian Medical Academies. In Lesotho, the MOH was involved in the program planning from the beginning. MOH support came largely in an advisory role, given the limited human and financial resources. As each program evolved, the MOH assumed primary programmatic and responsibility.
Each program also identifi ed other key collaborators, including laboratory networks and drug procurement groups. Each site had different challenges. In Peru, expanded culture capacity and DST using rapid methods were introduced. Russia had a strong laboratory infrastructure at the start of the program, and external support confi rmed the validity of DST methods being used by local laboratories. Lesotho had a central laboratory that was only capable of performing smear microscopy. With the collaboration of FIND, smear microscopy resources were expanded, and culture capacity and rapid DST were introduced. In all three sites, technical assistance included help to implement quality assurance and quality control procedures. Drug procurement also varied in the three settings: in Peru, drugs were originally obtained from a US hospital; the program then transitioned to GLC procurement with a central Lima pharmacy. Tomsk followed the same model, but also required central registration of medications. Lesotho was able to benefi t from the GLC at program initiation.
In all sites, links with other NGOs (e.g., community health organizations, the Red Cross, the Clinton Foundation) were crucial in maximizing resources and avoiding duplication of efforts. Other key collaborators depended on the setting. In Peru, laboratory and NTP directors needed to work together to develop a rational policy for DST testing. In Russia, collaboration between civilian and prison sector providers ensured standardized medical management and coordination of care for patients moving between sectors. In Lesotho, given the high rates of HIV, close coordination was needed between the HIV and TB programs.
Identifi cation of initial locus of care
PIH has advocated for the use of an 'accompaniment' model, i.e., medical, social, and economic support delivered by paid CHWs. 35, 36 While this model was used in each site, 37 the primary locus of care varied greatly. In Peru, the program started with a strong community-based component. All patients initiated and received most of their treatment in their homes. Local youth working in a community health program were readily trained to accompany MDR-TB patients through the end of their treatment. This remains the case in Peru currently. In Tomsk, patients routinely received treatment as in-patients until injectable treatment was discontinued. Community-based care with CHWs is reserved for the most at-risk individuals via the Sputnik program. Lesotho developed a combined community and hospital program. Most patients are so critically ill they require hospitalization for treatment initiation. Most are rapidly discharged and receive ongoing treatment supported by CHWs in their homes or in the community housing supported by the project.
Minimization of patient-incurred costs
Multiple potential patient-incurred costs were identifi ed in each site. These included costs related to diagnosis, medications for MDR-TB treatment and side effect management, transportation, work disruption, nutritional needs and housing. Programs worked to minimize these costs in different ways. In all three sites, patients received their medications for TB and side effects free of charge. Patients were also given access to improved diagnostic modalities free of charge in each site. Other potential patient-incurred costs were managed differently at each site. In Peru, nutritional support was provided via popular kitchens (comedores), where patients could have two meals a day free of charge. For patients needing to travel to referral centers, money was given during the fi rst year of treatment on a trip-by-trip basis. In Peru, housing was improved for families where ongoing household transmission was suspected due to overcrowded living conditions. In Tomsk, patients received nutritional support and daily transport costs to ambulatory sites. In Lesotho, patients were given monthly food packages for the family during the fi rst 6 months of treatment, which were continued if the patients began to lose weight. Program vehicles were used for patient transportation throughout treatment. In both Peru and Lesotho, community housing was provided for patients from remote regions. All three sites had fl exible DOT hours to allow patients to continue to work.
Targeted interventions for vulnerable populations
Each site identifi ed vulnerable populations at increased risk of contracting MDR-TB or doing poorly once infected. All three sites identifi ed populations living in poverty as vulnerable to MDR-TB. In Peru, strong family clustering of the disease was noted and contact monitoring was crucial. In Tomsk, prisoners and patients with substance abuse issues were found to be vulnerable and were actively supported. In Lesotho, HIV patients and mine workers were identifi ed as vulnerable populations. Universal screening and male outreach initiatives were established to address the needs of these groups.
Importance of technical assistance and funding
Each program required initial fi nancial support and long-term technical assistance. In Peru, MDR-TB treatment was not available, and global recommendations on MDR-TB management did not exist. Intensive technical assistance was thus provided, and experts remained heavily engaged in the fi rst 6 years of the program. The initial US$1.7 million were provided by private donations. In Russia, technical assistance was intense during the fi rst year of the program, but as more Russian providers became trained, assistance was provided on a quarterly basis. The initial US$2.2 million were provided by the OSI. In Lesotho, ongoing technical assistance was provided over a 2-year period, then reduced to an every-other-month basis. The initial US$3 million were provided by the OSI. All programs now have local leadership, and PIH provides ongoing technical assistance as needed. All three now receive the bulk of their fi nding from the Global Fund and their own NTPs ( Table 2) .
DISCUSSION
This article is a qualitative, operational analysis of three programs providing programmatic MDR-TB treatment. Rigorous qualitative methods were employed to provide setting/program analyses and a thematic analysis of overarching themes. The programs operate in vastly different geographic, cultural, economic, epidemiologic and health care settings, and all managed to implement successful MDR-TB programs. Six thematic areas emphasize 1) the importance of baselines assessments; 2) identifi cation of key collaborators, including the MOH, laboratory and procurement networks, while allowing for collaboration with organizations relevant to the affected populations in each area; 3) identifi cation of a primary locus of care, a component of which is community based; 4) minimization of patient-incurred costs by providing medications and diagnostics free of charge, as well as support for housing, transport and food; 5) identifi cation of and focused interventions with vulnerable populations such as family clusters, prisoners, substance users, HIV-positive persons and mine workers; and 6) provision of initial external technical and fi nancial assistance (in the US$2-3 million range) while transitioning to local leadership and funding from the Global Fund and MOH.
Ongoing costs and technical assistance for each of these projects are important areas of analysis. A cost-effectiveness analysis of these projects is forthcoming and beyond the scope of this article. It is believed that a substantial proportion of initial costs went into set-up and infrastructure building. Anecdotally, costs for medications have decreased significantly from Peru to Lesotho. Only Peru and Tomsk receive funding from their NTPs, and all three sites rely heavily on funding from the Global Fund. How costs will be controlled and assumed by NTPs is an important and unanswered question in programmatic management of MDR-TB.
The study has some notable limitations. Data were collected at different periods of time by different observers. Although the data were verifi ed by several members of the team, historical as well as interobserver bias may have occurred. The three program sites represent a wide array of experiences but these may not be generalizable to all global settings.
Many countries face enormous challenges in the implementation and scale-up of MDR-TB treatment programs, including high burdens of MDR-TB-such as China, India and the former Soviet Union-or a relative lack of existing infrastructure and convergence of HIV and TB epidemics, as is the case with many countries in sub-Saharan Africa. Our analysis suggests that efforts to understand the local context and to design site-specifi c strategies related to the six themes will aid in the implementation and expansion of national MDR-TB treatment programs. 
